With an overreliance on opioids and little innovation in the pain market, MindMed chief development officer, Rob Barrow, said the time is right to explore psychedelics for the treatment of pain.
“Evidence dating back to the 1950s suggests that LSD and other psychedelics may have analgesic effects, but this treatment area remains largely untapped by companies studying psychedelics, with the majority of research focusing solely on psychiatric indication,” said Barrow.Article content Previous studies have found that psychedelics may provide an analgesic benefit in cancer pain, phantom limb pain and cluster headaches, according to research published in theResearch from Joel P. Castellanos at the University of California San Diego has shown that psychedelics can alter the brain’s functional connectivity areas, per, and these adjustments could reduce pain associated with conditions like tinnitus and complex regional pain disorder.
“With the launch of Project Angie, we seek to align closely with MindMed’s core mission to improve mental health and combat substance use for the many patients in need,” said MindMed CEO and co-founder J.R. Rahn. “If we can help to develop a new paradigm to treat pain, it may have the potential to greatly reduce the use of addictive medicines such as opioids currently ravaging society and its mental health.
TheGrowthOp You should reach out to DrGChamberland and learn more about the current head to head studies of cannabinoids vs. morphine that are already underway at TetraBioPharma. extremesb